Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
European Journal of Medical Research|February 12, 2026
Phthalate exposure and hyperuricemia: the mediating role of obesityXia Ma, Xinran You, Shiping Zhu, et al.
Beilstein Journal of Nanotechnology|September 7, 2017
Group-13 and group-15 doping of germananeNicholas D Cultrara, Maxx Q Arguilla, Shishi Jiang, et al.
Journal of Experimental Botany|September 1, 2012
Proteomic analysis of Mn-induced resistance to powdery mildew in grapevineYin An Yao, Junru Wang, XueMei Ma, et al.
Plos One|May 11, 2012
A novel solid-phase site-specific PEGylation enhances the in vitro and in vivo biostabilty of recombinant human keratinocyte growth factor 1Zhifeng Huang, Guanghui Zhu, Chuanchuan Sun, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|November 19, 2011
Acceleration of diabetic-wound healing with PEGylated rhaFGF in healing-impaired streptozocin diabetic ratsZhifeng Huang, Meifei Lu, Guanghui Zhu, et al.
European Journal of Medicinal Chemistry|November 20, 2023
Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR/c-Met inhibitors for the treatment of NSCLCSheng Tang, Chuanchuan Sun, Xintao He, et al.
Plos One|June 16, 2011
A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycolZhifeng Huang, Huiyan Wang, Meifei Lu, et al.
International Immunopharmacology|January 27, 2025
Modulation of γδ T cells by USF3: Implications for liver fibrosis and immune regulationXianghong Wang, Rong Lin, Dehai Li, et al.
International Urology and Nephrology|September 25, 2025
The Global, regional, and national burden of type 1 diabetes mellitus-related chronic kidney disease, 1990-2021: Insights from the global burden of disease study 2021 and projections to 2050Yeye Yu, Haoying Sun, Chuanchuan Sun, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 16, 2022
XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancerShan Xu, Xin Sun, Leixuan Luo, et al.
Pageof 2